$ZVRA News

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $20

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $24

Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C

Zevra Therapeutics Receives Negative Opinion From EMA CHMP On Its Marketing Authorization Application For Arimoclomol For The Treatment Of Niemann-Pick Disease Type C

HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Zevra Therapeutics Announces Publication Of Arimoclomol In Infants With Niemann-Pick Disease Type C: Results From The Phase 2/3 Open-Label Pediatric Substudy In Molecular Genetics And Metabolism Reports

Maxim Group Maintains Buy on Zevra Therapeutics, Raises Price Target to $35

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $29

BTIG Reiterates Buy on Zevra Therapeutics, Raises Price Target to $27

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Raises Price Target to $29

Citizens Maintains Market Outperform on Zevra Therapeutics, Raises Price Target to $25

Cantor Fitzgerald Maintains Overweight on Zevra Therapeutics, Raises Price Target to $34

Zevra Therapeutics Submits U.S. Patent For MIPLYFFA To FDA For Listing In Orange Book Publication; Patent Expires On November 19, 2041

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Guggenheim Maintains Buy on Zevra Therapeutics, Raises Price Target to $25

Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?